Provectus Logo
Multimedia News

ASCO 2010 Presentation

Highlights and video from the poster presentation made at ASCO 2010


Provectus Updates Shareholders on 2009 Year-to-date Accomplishments

Progress Made In Therapies for Metastatic Melanoma, Atopic Dermatitis and Psoriasis

ASCO 2009 Presentation

Highlights and video from the poster presentation made at ASCO 2009


6th International Symposium on Melanoma and Other Cutaneous Malignancies

Professor John F. Thompson,M.D. presentated interim results of the phase 2 clinical trial of PV-10 for melanoma in March 2009.

Perspectives In Melanoma Conference XII Presentation

Professor John F. Thompson,M.D. presented interim results of Phase 2 PV-10 for melanoma trial in October 2008.


PV-10 for Melanoma Story Airs in Australia

Video interviews with Professor John Thompson and a patient who was involved in the Phase 2 study of PV-10 for melanoma.

SCC 2008 Presentation

Professor John Thompson of the Sydney Melanoma Unit presents preliminary findings from Phase 2 study of PV-10 for melanoma.


Provectus Preview

30 second preview of Provectus' multimedia annual report.

Clinical Trials Updates

Clinical trial information at ClinicalTrials.gov

Summary of the clinical effects of PV-10 on melanoma

Melanoma Research Publishes PV-10 Article

[video] PV-10 for melanoma story airs on Australian TV

Information on the Compassionate Use Program for PV-10

Subscribe to the Provectus News newsletter

Opening a New Front in the
War Against Cancer

Provectus Pharmaceuticals is developing advanced therapies designed to:

Provectus has developed groundbreaking biotechnologies to augment vaccine production and detect viruses (including an innovative “virus hunter” method); preparing to spinout the subsidiary that contains our novel over-the-counter skin care products; and seeks to license patented technologies for therapeutic and cosmetic medical devices.

For further information, read our detailed Research Reports.

 

In The Media    
August 18, 2010
Knox company enters clinical trial stage for cancer drug

An article, entitled "Knox company enters clinical trial stage for cancer drug", appearing in the Knoxville News Sentinel, highlights Provectus' preparation for a Phase 3 trial of PV-10 for metastatic melanoma.

August 9, 2010
Cancerwatch Publishes Article on PV-10 for Melanoma

An article on PV-10 for metastatic melanoma was published in the July 2010 edition of Cancerwatch.

July 19, 2010
Oncology NEWS International Article Contains Sidebar on PV-10 for Melanoma

An article on Ipilimumab appearing in Oncology NEWS International contains a sidebar on PV-10 for metastatic melanoma

July 8, 2010
HemOnc Today News Brief Highlights PV-10 for Melanoma

A news brief appearing in HemOnc Today titled "Rose bengal active in metastatic melanoma" briefly summarizes positive results from the Phase 2 clinical trial of PV-10 for metastatic melanoma.

July 7, 2010
Practical Dermatology Reports on Promising New Investigational Melanoma Therapies

In an article titled "Promising Data on Ipilimumab and Other Investigational Melanoma Therapies", appearing in the July 2010 issue of Practical Dermatology, Jonathan Wolfe, MD discusses promising findings on potential new treatments for advanced melanoma, including PV-10.

June 10, 2010
Chemoablation of Metastatic Melanoma with Rose Bengal Shows Robust Response: Presented at ASCO

Doctor's Guide published an article 06.09.2010 titled "Chemoablation of Metastatic Melanoma with Rose Bengal Shows Robust Response: Presented at ASCO" reporting on the Phase 2 PV-10 for metastatic melanoma clinical data presented at ASCO 2010 by lead investigator Sanjiv Agarwala, MD.


Press Releases    
August 25, 2010
Provectus Pharmaceuticals Will Present at the Rodman & Renshaw 12th Annual Healthcare Conference on September 14, 2010

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB: PVCT http://www.pvct.com) will present at the Rodman & Renshaw 12th Annual Healthcare Conference in New York City on September 14, 2010 at 3:15 p.m. Eastern Time. The conference will be held at the New York Palace Hotel.

Read the complete article here.

July 27, 2010
Provectus Pharmaceuticals to Use Numoda's TruPoints System to Facilitate Transactions with Potential Licensing Partners for PH-10

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB: PVCT http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, has signed an agreement with Numoda Capital Innovations LLC (http://www.numodacapital.com) to license its TruPoints strategic partnering platform.

Read the complete article here.

July 15, 2010
Provectus Pharmaceuticals Reports Achieved Milestones for First Half of 2010, Recent Developments and Plans for the Remainder of the Year to Shareholders

KNOXVILLE, Tenn., July 15 --(BUSINESS WIRE)-- Provectus Pharmaceuticals, Inc. (OTCBB: PVCT http://www.pvct.com) reports on its first half 2010 clinical and corporate accomplishments, as well as its clinical development plans, in a letter to shareholders from Craig Dees, Ph.D., CEO of Provectus.

Read the complete article here.

June 07, 2010
Provectus Reports Encouraging Data on Visceral Metastases Presented at ASCO

KNOXVILLE, Tenn., June 7 /PRNewswire-FirstCall/ -- Provectus Pharmaceuticals, Inc. (OTCBB: PVCT http://www.pvct.com) has announced additional positive data from its Phase 2 clinical trial of PV-10 for metastatic melanoma. The data, on changes in visceral and nodal metastases following chemoablation of cutaneous melanoma lesions with PV-10, was presented by Dr. Sanjiv Agarwala at the American Society of Clinical Oncology 2010 Annual Meeting, on Sunday, June 6, 2010, in the General Poster Session on Melanoma/Skin Cancers, Abstract #8534. Positive improvement observed in these remote, untreated lesions, including metastases to the lungs, liver and brain, illustrate a potential systemic effect in visceral organs to which melanoma has spread. Dr. Agarwala's updated information included data from both the initial 40 subjects and the final 40 subjects enrolled in the Phase 2 trial.

Read the complete article here.

May 21, 2010
Provectus Reports Further Positive Phase 2 Data on PV-10 for Metastatic Melanoma at ASCO

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB: PVCT http://www.pvct.com) has announced further positive data on the first forty subjects in its Phase 2 clinical trial of PV-10 for metastatic melanoma, with an objective response ("OR") observed in 61% of subjects and a mean Progression Free Survival ("PFS") of at least 11.1 months among those subjects achieving an OR.

Read the complete article here.

April 29, 2010
Provectus Reports on Successful End-of-Phase 2 Meeting with U.S. FDA and Gains Clarity for Licensure of PV-10 for Metastatic Melanoma

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB: PVCT http://www.pvct.com) announced today that it has held an end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) to seek consensus on clinical program scope and endpoints for licensure of PV-10 for metastatic melanoma. The meeting was held at the Agency's White Oak Campus in Silver Spring, MD.

Read the complete article here.